HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results
March 23 2017 - 4:03PM
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of
instruments, reagents and services for molecular profiling
applications, today reported financial results for the fourth
quarter and year ended December 31, 2016.
Recent Accomplishments &
Highlights:
- Signed a development, manufacturing and commercialization
agreement with a wholly owned affiliate of QIAGEN, N.V.•
QIAGEN North American Holdings also made a minority
investment in HTG’s common stock• Completed technical
feasibility assay for QIAGEN GeneReader next-generation sequencing
platform
- Obtained CE marking for the HTG EdgeSeq ALKPlus Assay for
commercialization of the assay as an in vitro diagnostic (IVD) in
the European Union
- Announced availability of new direct sequencing chemistry and
initial DNA mutation assay as a service offering in the company’s
VERI/O laboratory
- Achieved revenue of $1.5 million for the fourth quarter of 2016
compared to $1.2 million in Q4 2015• Service revenue
increased to $381,000 in the fourth quarter of 2016 from $33,000 in
Q4 2015
- Achieved revenue of $5.1 million for the year ended December
31, 2016 compared to $4.0 million for the year ended December 31,
2015• Service revenue increased to $2.4 million in 2016 from
$184,000 in 2015
“In 2016, we believe HTG made significant strides in customer
adoption and building a solid platform for long-term growth,” said
TJ Johnson, HTG’s President and CEO.
Fourth Quarter 2016 Financial
Results:
Revenue for the fourth quarter of 2016 was $1.5 million. Net
loss from operations was $5.2 million for the fourth quarter of
2016, compared to $5.3 million for the fourth quarter of 2015. Net
loss per share was $(0.76) for the fourth quarter of 2016 and
$(0.83) for the fourth quarter of 2015.
Full Year 2016 Financial Results:
Revenue for the year ended December 31, 2016 was $5.1
million. Net loss from operations for the year ended
December 31, 2016 was $24.3 million, compared to $18.9 million
for the year ended December 31, 2015. Net loss per share was
$(3.66) for the year ended December 31, 2016 and $(5.03) for
the year ended December 31, 2015. HTG ended 2016 with $11.8
million in total cash and investments, including $7.5 million in
cash and equivalents and $4.3 million in short term
available-for-sale investments, and current liabilities of
approximately $10.0 million plus an additional $14.0 million in
long-term liabilities.
Conference Call
HTG will host an investment community conference call today
beginning at 5:00 p.m. ET. Individuals interested in listening to
the conference call may dial (866) 394-4225 for domestic
callers, or (678) 509-7535 for international callers,
conference ID 91525538, or access the webcast on the investor
relations section of the Company’s website at:
www.htgmolecular.com. The webcast will be available on the
Company’s website for 90 days following the completion of the
call.
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower
precision medicine at the local level. In 2013, the company
commercialized its first instrument platform and a portfolio of RNA
assays that leveraged HTG's original proprietary nuclease
protection chemistry. Continuous improvement led to the 2014 launch
of the company’s HTG EdgeSeq product line, which automates sample
and targeted library preparation for next-generation sequencing.
Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding our growth prospects, and
strategic priorities. Words such as “believes,” “anticipates,”
“plans,” “expects,” “intends,” “will,” “goal,” “potential” and
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements necessarily
contain these identifying words. These forward-looking statements
are based upon management’s current expectations, are subject to
known and unknown risks, and involve assumptions that may never
materialize or may prove to be incorrect. Actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of various risks and
uncertainties, including, without limitation, risks associated with
our ability to enter into new collaborations with Pharma customers,
risks associated with our ability to obtain regulatory clearances
or approvals in the United States and other jurisdictions to market
panels for diagnostic purposes, our ability to successfully
commercialize our products; our ability to manufacture our products
to meet demand; the level and availability of third party payor
reimbursement for our products; our ability to effectively manage
our anticipated growth; our ability to protect our intellectual
property rights and proprietary technologies; our ability to
operate our business without infringing the intellectual property
rights and proprietary technology of third parties; competition in
our industry; requirements for additional capital and credit
availability; our ability to attract and retain qualified
personnel; and product liability claims. These and other factors
are described in greater detail in our filings with the Securities
and Exchange Commission, including without limitation our Annual
Report on Form 10-K for the year ended December 31, 2016. All
forward-looking statements contained in this press release speak
only as of the date on which they were made, and we undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
-Financial tables follow-
HTG Molecular Diagnostics, Inc. |
|
Statements of Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|
|
Years Ended December 31, |
|
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
1,076,560 |
|
|
$ |
1,182,287 |
|
|
$ |
2,759,942 |
|
|
$ |
3,532,028 |
|
Service |
|
|
381,221 |
|
|
|
33,466 |
|
|
|
2,372,788 |
|
|
|
183,758 |
|
Other |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
325,789 |
|
Total revenue |
|
|
1,457,781 |
|
|
|
1,215,753 |
|
|
|
5,132,730 |
|
|
|
4,041,575 |
|
Cost of revenue |
|
|
1,234,429 |
|
|
|
796,921 |
|
|
|
4,135,884 |
|
|
|
3,335,511 |
|
Gross margin |
|
|
223,352 |
|
|
|
418,832 |
|
|
|
996,846 |
|
|
|
706,064 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administrative |
|
|
4,083,832 |
|
|
|
4,111,249 |
|
|
|
17,427,777 |
|
|
|
14,994,410 |
|
Research
and development |
|
|
1,384,503 |
|
|
|
1,650,709 |
|
|
|
7,900,311 |
|
|
|
4,601,718 |
|
Total operating
expenses |
|
|
5,468,335 |
|
|
|
5,761,958 |
|
|
|
25,328,088 |
|
|
|
19,596,128 |
|
Operating loss |
|
|
(5,244,983 |
) |
|
|
(5,343,126 |
) |
|
|
(24,331,242 |
) |
|
|
(18,890,064 |
) |
Loss from change in
stock warrant valuation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(239,683 |
) |
Interest expense,
net |
|
|
(425,649 |
) |
|
|
(348,443 |
) |
|
|
(1,755,053 |
) |
|
|
(1,633,616 |
) |
Loss on settlement of
convertible debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(705,217 |
) |
Other |
|
|
3,410 |
|
|
|
2,105 |
|
|
|
56,863 |
|
|
|
80,978 |
|
Net loss before income
taxes |
|
|
(5,667,222 |
) |
|
|
(5,689,463 |
) |
|
|
(26,029,432 |
) |
|
|
(21,387,602 |
) |
Income taxes |
|
|
5,859 |
|
|
|
10,189 |
|
|
|
10,118 |
|
|
|
10,189 |
|
Net loss |
|
|
(5,673,081 |
) |
|
|
(5,699,652 |
) |
|
|
(26,039,550 |
) |
|
|
(21,397,791 |
) |
Accretion of redeemable
convertible preferred stock discount, issuance costs and
dividends |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,328,594 |
) |
Net loss attributable
to common stockholders |
|
$ |
(5,673,081 |
) |
|
$ |
(5,699,652 |
) |
|
$ |
(26,039,550 |
) |
|
$ |
(22,726,385 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share
attributable to common stockholders, basic and diluted |
|
$ |
(0.76 |
) |
|
$ |
(0.83 |
) |
|
$ |
(3.66 |
) |
|
$ |
(5.03 |
) |
Shares used in
computing net loss per share attributable to common stockholders,
basic and diluted |
|
|
7,488,842 |
|
|
|
6,840,918 |
|
|
|
7,113,075 |
|
|
|
4,518,499 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HTG Molecular Diagnostics, Inc. |
|
Balance Sheets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2016 |
|
|
2015 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
7,507,659 |
|
|
$ |
3,293,983 |
|
Short-term investments available-for-sale, at fair value |
|
|
4,304,901 |
|
|
|
28,201,507 |
|
Accounts
receivable |
|
|
1,377,441 |
|
|
|
716,246 |
|
Inventory, net |
|
|
1,511,053 |
|
|
|
2,201,301 |
|
Prepaid
expenses and other |
|
|
433,328 |
|
|
|
445,217 |
|
Total current
assets |
|
|
15,134,382 |
|
|
|
34,858,254 |
|
|
|
|
|
|
|
|
|
|
Long-term
investments available-for-sale, at fair value |
|
|
— |
|
|
|
2,603,901 |
|
Deferred
offering costs |
|
|
49,630 |
|
|
|
— |
|
Property
and equipment, net |
|
|
3,270,197 |
|
|
|
1,932,213 |
|
Total assets |
|
$ |
18,454,209 |
|
|
$ |
39,394,368 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and
stockholders' equity (deficit) |
|
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
|
Accounts
payable |
|
$ |
761,663 |
|
|
$ |
724,805 |
|
Accrued
liabilities |
|
|
1,670,286 |
|
|
|
1,915,268 |
|
Deferred
revenue |
|
|
335,659 |
|
|
|
47,476 |
|
NuvoGen
obligation |
|
|
604,751 |
|
|
|
543,750 |
|
Term
loan |
|
|
6,389,782 |
|
|
|
3,059,068 |
|
Other
current liabilities |
|
|
258,850 |
|
|
|
29,243 |
|
Total current
liabilities |
|
|
10,020,991 |
|
|
|
6,319,610 |
|
Term loan payable -
non-current, net of discount and debt issuance costs |
|
|
5,389,137 |
|
|
|
7,737,586 |
|
NuvoGen obligation -
non-current, net of discount |
|
|
8,017,356 |
|
|
|
8,415,122 |
|
Other |
|
|
619,587 |
|
|
|
28,652 |
|
Total liabilities |
|
|
24,047,071 |
|
|
|
22,500,970 |
|
Commitments and
Contingencies |
|
|
|
|
|
|
|
|
Total stockholders’
equity (deficit) |
|
|
(5,592,862 |
) |
|
|
16,893,398 |
|
Total liabilities and
stockholders' equity (deficit) |
|
$ |
18,454,209 |
|
|
$ |
39,394,368 |
|
|
|
|
|
|
|
|
|
|
Contact:
Westwicke Partners
Jamar Ismail
Phone: (415) 513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostic
Phone: (520) 547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2024 to May 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From May 2023 to May 2024